Hyderabad: India’s COVID-19 vaccine, Corbevax, has been granted an Emergency Use Listing by the World Health Organisation, the company which manufactures it in India said Hyderabad today. Corbevax is based on a protein sub-unit platform and manufactured by the pharmaceutical firm Biological E Limited in India.
Read More: Budget 2024: Meet Nirmala Sitharaman’s Key Team in Shaping Interim Budget This Year
Mahima Datla, Managing Director of Biological E Ltd said: “We are pleased with the WHO Emergency Use Listing (EUL) because it would help us use the platform to continue developing COVID-19 vaccines as and when it starts impacting public health. We are confident that this endorsement from WHO will bolster our global fight against COVID-19.”
The Drugs Controller General of India (DCGI) had already approved Corbevax for restricted use in emergency among adults, adolescents and young children in a sequential manner from December 2021 to April 2022.
Read More: Quantum technologies in information security intersects with cyber-terrorism attacks
It was also given approval for use as India’s first heterologous COVID-19 booster shot for adults aged 18 and above, in June 2022.
The company supplied 100 million doses of Corbevax to the central government which were then utilized in pan-India immunization campaigns, mainly in children aged 12-14 years, the release said.
Read More: Interim Budget 2024: Govt may revise tax exemption in lower bracket for Old Tax regime, say sources
Datla said that several companies which started vaccine development or manufacture during the COVID-19 pandemic exited later due to paucity of funds or lack of success. However, BE continued to remain committed to develop and provide access to high quality and affordable vaccines globally, by constantly enlarging its portfolio of offerings, she added.
